ADC for SCLC Clears Phase I.
1/5 보강
ZL-1310, an antibody-drug conjugate that targets DLL3-expressing small cell lung cancer cells, led to responses in nearly half of patients in a phase I study.
APA
(2026). ADC for SCLC Clears Phase I.. Cancer discovery, 16(1), OF1. https://doi.org/10.1158/2159-8290.CD-NW2025-0107
MLA
. "ADC for SCLC Clears Phase I.." Cancer discovery, vol. 16, no. 1, 2026, pp. OF1.
PMID
41405207
Abstract
ZL-1310, an antibody-drug conjugate that targets DLL3-expressing small cell lung cancer cells, led to responses in nearly half of patients in a phase I study. These results provide further evidence that targeting DLL3 may be a promising approach for treating this cancer.